Literature DB >> 19519199

Aflibercept in epithelial ovarian carcinoma.

John W Moroney1, Anil K Sood, Robert L Coleman.   

Abstract

Angiogenesis is a hallmark of malignant transformation. With improved understanding of angiogenic signaling in both the normal and malignant state, there have been a number of agents developed that target VEGF signaling. These targeted agents can affect downstream VEGF signal transduction via unique mechanisms at different cellular and extracellular locations. The aflibercept, or VEGF-Trap, molecule is the subject of this article. Its molecular structure, pharmacokinetic and pharmacodynamic profile, and preclinical and early clinical data in epithelial ovarian carcinoma is reviewed. For comparison, other anti-angiogenic agents that have been or are currently being studied in epithelial ovarian carcinoma are also summarized. Finally, the anticipated role of aflibercept in the treatment of epithelial ovarian carcinoma is also discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19519199      PMCID： PMC2744352          DOI： 10.2217/fon.09.35

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  21 in total

Review 1.  Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.

Authors:  Jocelyn Holash; Gavin Thurston; John S Rudge; George D Yancopoulos; Alex A Adjei; Gabriele Bergers; Bronislaw Pytowski; Mark Pegram; Michael S Gordon
Journal:  Cancer Metastasis Rev       Date:  2006-06       Impact factor: 9.264

2.  The discovery of the placental growth factor and its role in angiogenesis: a historical review.

Authors:  Domenico Ribatti
Journal:  Angiogenesis       Date:  2008-06-21       Impact factor: 9.596

3.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

4.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

Authors:  Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

5.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Authors:  Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

6.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.

Authors:  John S Rudge; Jocelyn Holash; Donna Hylton; Michelle Russell; Shelly Jiang; Raymond Leidich; Nicholas Papadopoulos; Erica A Pyles; Al Torri; Stanley J Wiegand; Gavin Thurston; Neil Stahl; George D Yancopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

Review 8.  VEGF-targeted therapy: mechanisms of anti-tumour activity.

Authors:  Lee M Ellis; Daniel J Hicklin
Journal:  Nat Rev Cancer       Date:  2008-07-03       Impact factor: 60.716

9.  Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.

Authors:  Henk M W Verheul; Hans Hammers; Karen van Erp; Yonfeng Wei; Tolib Sanni; Brenda Salumbides; David Z Qian; George D Yancopoulos; Roberto Pili
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

10.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482
View more
  11 in total

1.  Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat; Susan C Modesitt; Kathleen M Schmeler; Revathy B Iyer; Michael E Garcia; Debbie L Miller; Edward F Jackson; Chaan S Ng; Vikas Kundra; Robert Jaffe; Anil K Sood
Journal:  Lancet Oncol       Date:  2011-10-10       Impact factor: 41.316

Review 2.  Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

Authors:  Rebecca L Stone; Anil K Sood; Robert L Coleman
Journal:  Lancet Oncol       Date:  2010-03-10       Impact factor: 41.316

3.  Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

Authors:  Hiroaki Itamochi
Journal:  World J Biol Chem       Date:  2010-07-26

Review 4.  Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

Review 5.  Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Fu Shen; Zhang Qing; Guo Xiao-Mao
Journal:  Tumour Biol       Date:  2014-07-30

6.  Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121.

Authors:  Yin Zhang; Hao Hong; Gang Niu; Hector F Valdovinos; Hakan Orbay; Tapas R Nayak; Xiaoyuan Chen; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2012-11-16       Impact factor: 4.939

Review 7.  In pursuit of new anti-angiogenic therapies for cancer treatment.

Authors:  Jun Cai; Song Han; Ruan Qing; Daiqing Liao; Brian Law; Michael E Boulton
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

Review 8.  Heterotypic cellular interactions in the ovarian tumor microenvironment: biological significance and therapeutic implications.

Authors:  Honami Naora
Journal:  Front Oncol       Date:  2014-02-06       Impact factor: 6.244

9.  Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma.

Authors:  Dong Yoon Kim; Jeong A Choi; Jae-Young Koh; Young Hee Yoon
Journal:  J Exp Clin Cancer Res       Date:  2016-11-04

Review 10.  Targeting the Microenvironment in High Grade Serous Ovarian Cancer.

Authors:  Nkechiyere G Nwani; Livia E Sima; Wilberto Nieves-Neira; Daniela Matei
Journal:  Cancers (Basel)       Date:  2018-08-10       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.